Pharmaceutical Industry 20 – 26 July: Ft NICE and EpilepsyGTx
- NICE has issued final draft guidance recommending Bayer’s finerenone for adults with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above.
- EpilepsyGTx has partnered with ClearPoint Neuro to support the precise, MRI-guided administration of its EPY201 gene therapy candidate.
The pharmaceutical industry has recorded progress across two markedly different but equally challenging areas of medicine, as Bayer welcomes a major recommendation for its heart failure treatment finerenone and EpilepsyGTx selects ClearPoint Neuro’s technology to support the clinical development of a targeted epilepsy gene therapy.
In cardiovascular care, NICE has issued final draft guidance recommending finerenone for adults in England and Wales with symptomatic chronic heart failure and a left ventricular ejection fraction, or LVEF, of 40% or above.
The development expands the potential use of the non-steroidal mineralocorticoid receptor antagonist into heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. These are conditions that affect a significant proportion of heart failure patients but have historically presented clinicians with limited treatment options.
Meanwhile, EpilepsyGTx has entered into a partnership with ClearPoint Neuro to enable the targeted administration of EPY201, its lead gene therapy candidate for focal refractory epilepsy, as the programme moves towards first-in-human phase 1/2a clinical trials.
Together, the announcements underline the breadth of pharmaceutical innovation currently taking place, from expanding access to an evidence-based cardiovascular medicine through NHS pathways to preparing an advanced gene therapy for precision delivery directly into the brain.
NICE Recommendation Expands Heart Failure Treatment Options
Bayer described the NICE recommendation for finerenone as an important milestone for people living with symptomatic chronic heart failure and an LVEF of 40% or above.
The guidance covers patients with heart failure with mildly reduced ejection fraction, commonly known as HFmrEF, and heart failure with preserved ejection fraction, known as HFpEF.
These forms of heart failure represent a substantial and growing clinical challenge. While the heart may continue to pump a relatively normal proportion of blood with each contraction, it can still struggle to fill, relax or function efficiently enough to meet the body’s needs.
Patients may consequently experience breathlessness, fatigue, fluid retention and reduced physical capacity. Many also face repeated hospital admissions, worsening quality of life and an elevated risk of cardiovascular complications and death.
A consultant cardiologist and heart failure lead at the Royal Free Hospital in London said that HFpEF and HFmrEF represent a growing challenge for patients, clinicians and the NHS.
They warned that too many patients continue to experience recurrent hospitalisation, poor quality of life and an unacceptably high risk of death.
As the population ages and the burden of heart failure rises, improving outcomes for this large and historically underserved patient group is becoming increasingly important. The recommendation of finerenone therefore gives clinicians an additional evidence-based treatment option that could help address a significant area of unmet need.
Heart Failure Burden Expected to Rise Sharply
Heart failure already affects more than one million people in the United Kingdom, placing considerable pressure on primary care, hospital cardiology departments and emergency services.
The prevalence of the condition in England is projected to increase by 92% by 2040, bringing the number of people affected close to two million.
Around half of heart failure patients are estimated to have an ejection fraction of 40% or above. HFpEF accounts for a substantial proportion of these cases and is particularly associated with older populations and patients living with multiple long-term health conditions.
The scale of the eligible population means the NICE recommendation could have wide-reaching implications for heart failure services. Providing clinicians with another treatment option may support more individualised care while helping to reduce the frequency of serious heart failure events.
However, the recommendation will also require coordinated implementation across NHS pathways, including patient identification, prescribing decisions, monitoring and long-term follow-up.
FINEARTS-HF Study Supports Finerenone Recommendation
The NICE decision follows authorisation from the Medicines and Healthcare products Regulatory Agency earlier in the year.
It is supported by results from the phase 3 FINEARTS-HF study, which evaluated finerenone in 6,001 adults with heart failure and an LVEF of 40% or above.
Over a median period of approximately 32 months, finerenone reduced the combined risk of cardiovascular death and total heart failure events by 16% compared with placebo.
The reported benefits were consistent across all pre-specified patient subgroups, suggesting that the treatment’s effects were not restricted to a narrow section of the trial population.
Finerenone was also generally well tolerated during the study, an important consideration for a patient population that is often older and may already be receiving several treatments for cardiovascular disease and other health conditions.
The chief executive officer of Bayer UK and Ireland said the company was delighted that NICE had recommended finerenone for patients with symptomatic chronic heart failure and an LVEF of 40% or above.
They described the guidance as an important milestone in expanding treatment options for people living with a complex and challenging condition.
EpilepsyGTx and ClearPoint Neuro Prepare EPY201 for Clinical Trials
While Bayer’s development concerns the expansion of an established pharmaceutical treatment, EpilepsyGTx and ClearPoint Neuro are preparing to enter a much earlier and more technically demanding stage of clinical development.
EpilepsyGTx has partnered with ClearPoint Neuro to support the targeted delivery of EPY201 ahead of planned first-in-human phase 1/2a trials in focal refractory epilepsy.
Under the partnership, EpilepsyGTx will use the ClearPoint SmartFlow Cannula and ClearPoint Neuro Navigation system to administer EPY201 directly into the area of the brain where a patient’s seizures originate.
The MRI-guided platform is designed to provide sub-millimetric accuracy, alongside real-time visualisation of the treatment as it is delivered to the defined neurological target.
This level of precision is considered central to the EPY201 programme because the gene therapy is intended to act locally within the seizure focus while limiting exposure to surrounding regions of the brain.
Addressing a Devastating Form of Epilepsy
Focal epilepsy is a group of neurological disorders in which seizures begin within a specific region of the brain.
When seizures continue despite the use of at least two tolerated, appropriately selected anti seizure medicines, the condition is considered refractory or drug-resistant.
Focal refractory epilepsy affects approximately 10 million people worldwide, including an estimated two million people across the United States, UK and European Union.
For affected patients, uncontrolled seizures can have a severe impact on independence, employment, education and overall quality of life. The condition can also increase the risk of injury, hospitalisation and premature death.
Some patients may be considered for surgery, including the resection or ablation of the brain tissue associated with seizure activity. However, these procedures are not suitable for everyone, particularly when the seizure focus is located near regions responsible for essential neurological functions.
EPY201 is being developed as an alternative targeted approach. It is designed for direct administration into the seizure focus, where it aims to reduce neuronal hyperexcitability without producing widespread exposure across the brain.
Should the programme prove successful in clinical studies, it could potentially provide a single, minimally invasive treatment option that avoids the removal or destruction of brain tissue.
Precision Delivery Is Central to EPY201’s Potential
The chief executive officer of EpilepsyGTx said that accurate delivery to the seizure focus is central to the potential of EPY201 in focal refractory epilepsy.
They explained that ClearPoint’s guided navigation system provides the precision and intraprocedural visualisation required as the company prepares to evaluate the therapy in first-in-human trials.
EpilepsyGTx said it looks forward to working with ClearPoint to support the safe and targeted administration of EPY201 for people living with focal refractory epilepsy.
ClearPoint’s navigation system is already installed at more than 100 clinical sites worldwide. It has been used to support gene and cell therapy procedures across preclinical research, authorised clinical trials and commercial applications.
The chief business officer and general manager of biologics and drug delivery at ClearPoint Neuro described focal refractory epilepsy as a devastating condition affecting millions of patients.
They said the company was pleased to partner with EpilepsyGTx as it advances its targeted gene therapy programme into clinical evaluation.
The collaboration illustrates the increasingly close relationship between pharmaceutical development, medical devices and image-guided surgical technologies. For therapies administered directly into complex organs such as the brain, the delivery system can be just as important to the overall treatment strategy as the biological product itself.
Impact on Pharmaceutical Manufacturing and Production
The Bayer and EpilepsyGTx developments create different but equally important considerations for pharmaceutical manufacturing and production.
For Bayer, a positive NICE recommendation could lead to increased demand for finerenone as NHS adoption develops. Manufacturers will need to ensure that production capacity, quality control, packaging and distribution arrangements can support a potentially large eligible population without disrupting existing supply.
The projected increase in heart failure prevalence also demonstrates why manufacturers must plan beyond immediate launch volumes. Reliable long-term production will be essential if finerenone becomes more widely incorporated into routine cardiovascular treatment pathways.
The EPY201 programme presents a more specialised manufacturing challenge. Gene therapies require tightly controlled and highly consistent production processes, particularly when a product is intended for direct administration into the brain.
Production must also be coordinated with the equipment and clinical procedures used to deliver the therapy. EpilepsyGTx and ClearPoint will therefore need to align therapy supply, device availability, clinical-site readiness and procedural training as the programme advances.
More broadly, the partnership reflects a change in how advanced pharmaceutical products are being developed.
Manufacturers are no longer producing only a medicine in isolation. In many cases, they are contributing to a complete treatment system that combines a biological therapy, a delivery device, imaging technology, clinical expertise and detailed procedural controls.
This creates additional complexity, but it may also improve treatment precision and enable therapies to reach diseases that have previously been difficult to address safely.
Pharmaceutical Innovation Moves Closer to Patients
The two announcements sit at different points of the pharmaceutical development pathway.
Finerenone has already passed through large-scale phase 3 evaluation, regulatory authorisation and health technology assessment. The focus is now shifting towards patient access and implementation within NHS care.
EPY201, by contrast, is approaching its first evaluation in humans. Its safety, tolerability and potential effectiveness will need to be carefully established through clinical trials before any wider conclusions can be reached.
Nevertheless, both developments are linked by a common objective: improving treatment options for patient populations facing substantial unmet medical need.
Bayer is working to expand the therapeutic choices available to adults with forms of heart failure that have historically been difficult to treat. EpilepsyGTx and ClearPoint Neuro are preparing to test whether gene therapy and precision neurological delivery can offer a new option for people whose seizures remain uncontrolled despite existing medicines.
Conclusion
Bayer’s NICE recommendation and the partnership between EpilepsyGTx and ClearPoint Neuro highlight two distinct routes through which pharmaceutical innovation can reach patients.
For people living with symptomatic chronic heart failure and an LVEF of 40% or above, finerenone provides clinicians with an additional evidence-based treatment option supported by results from a large phase 3 study.
With heart failure prevalence expected to rise sharply over the coming years, its introduction into NHS pathways could become increasingly significant.
For patients with focal refractory epilepsy, EPY201 remains at a much earlier stage. However, the use of ClearPoint’s MRI-guided navigation and delivery technology provides the programme with a highly targeted route into first-in-human clinical evaluation.
One development is centred on expanding access to a proven cardiovascular medicine. The other is preparing a precision gene therapy for an area of neurological disease in which patients may otherwise face invasive surgery or continued uncontrolled seizures.
Together, they demonstrate an industry moving in two complementary directions: broadening access to treatments that can benefit large patient populations, while also building increasingly specialised therapies capable of reaching highly specific biological targets.
News Credits:
NICE backs finerenone for heart failure
EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy
Vous aimerez peut-être aussi :